How the press helps push prescription drugs, sometimes with deadly consequencesLast December, Sepracor, a company in Marlborough, Massachusetts, whose core business is concocting slight variations of the world's best-selling drugs, got the go-ahead from the Food and Drug Administration to sell Lunesta, a new sleeping pill that could be used for months without losing its effectiveness.

Sanofi-Aventis boosted DTC promotion for its Ambien franchise from $2 million to $160 million to support the lunesta no prescription launch of a new extended-release version, Ambien CR. Meanwhile, on the consumer side, McCann HumanCare's graceful butterfly icon and tag line-Leave the rest to Lunesta-took flight across TV, print and interactive media. A third brand-Takeda Pharmaceuticals North America's Rozerem (ramelteon)-came on the market in October, and with the original Ambien due to lose patent protection this year, Sanofi-Aventis has unleashed an aggressive Lunesta no prescription ad campaign for Ambien CR, which boasts a much stronger positioning against Lunesta than did the original formulation.

Some of it may have gone toward a 10% lunesta no prescription rise in spending for Crestor, as AZ sought to maintain the cholesterol drug's profile despite safety issues. As of press time, data for the full fourth quarter lunesta no prescription were not available, both data firms said. Bagley told the Times that Lunesta could reduce road lunesta no prescription rage since there'll be a lot more well-rested people out there. In the Post she said she was counting the days until she could get a prescription. The Lunesta brand team viewed insomnia as a condition that needed to come out of the dark, he says. While most of the eight FDA-approved sleep aids tend to lose their effectiveness after a week lunesta no prescription or so of use, Lunesta has been shown in Sepracor-funded clinical studies to remain effective for up to six months. Primary care physicians often neglect to raise the issue, and when they do, it happens lunesta no prescription as patients get up to leave the exam room. It was an important story, says Richard lunesta no prescription gelula, the foundation's chief executive officer. Lunesta no prescription the problem has grown dramatically in recent years as direct-to-consumer advertising has increased, delivering ever-higher ad revenues to the nation's media. But with Lunesta (eszopiclone), Sepracor saw an opening. Lunesta is so far the only prescription sleep aid approved by the Food and Drug Administration for long-term use, in contrast with more established short-term medications such as Ambien and Sonata.
Lunesta is projected to exceed $750 million in sales by 2009. Marketing Team of the Year, Small Pharma Lunesta Sepracor had a steep hill to climb when it brought Lunesta to market last year. Rounding out the top ten were spots for GSK's Boniva; Merck/Schering-Plough's Vytorin; Merck's Fosamax; and GSK's Valtrex.